<analysis>
**Action 1 (handoff pre-validation).** Carrying this out needs three things.
- **Real transcripts.** The monitoring team must pull 25 or more real Claude-Next handoffs from partner traffic, and Apollo's authors must be allowed to see them. The Glasswing reuse restrictions apply to real partner data, not just synthetic lookalikes. Counsel squeezed a side letter through in December, but raw partner handoffs are a harder ask. It may take redaction, and redaction itself changes the surface features.
- **Capacity.** The monitoring team has a 3-day backlog and eight contractors.
- **Reporting.** Results must reach CAISI within 48 hours.

This action's P(failure) covers only these execution risks. Whether the plants actually separate from real traffic is Threat 1's job. The December precedent (AUC 0.94 on surface features) is the base rate. With only 9 plants, the confidence interval is roughly ±0.2, so a statistically defensible pass is hard even if the point estimate lands under 0.60.

**Action 2 (main run).** It depends on Action 1 passing. The timing is also tight: main-run criteria must be pre-registered by 8 March, possibly before handoff pre-validation finishes. The harder problem is the stated gate of AUC below 0.55 on plant-versus-real. The non-handoff channels sat at 0.58 in pre-validation, and nothing in the plan improves the plants before the run. Even with a clean handoff result, meeting the 0.55 gate across all 4 channels by 23 March is unlikely. The fallback, strengthening the disclosure language, is easy to do, but it feeds the board's parallel track. Under the full plan, P(failure) is high.

**Action 3 (CAISI briefing).** Getting the meeting is routine. The substance, though, repeats February's failed either/or pitch, and the working text is already settled on leaving methods to CAISI guidance. Getting the quantitative-disclosure specifics into text written before 24 March is an uphill task. Informing UK AISI is trivial.

**Action 4 (Site 3 to 8 sessions).** One biosafety officer is the binding constraint. Sites 1 and 2 lost roughly 40% of their slots, and nine slots are booked in order to land six sessions. Reaching 6 is moderately likely, and reaching 4 or 5 is likely.

**Action 5 (Blumenthal report).** The template was pre-agreed and staff are engaged, so execution is routine. The risk from the "monitored continuously" wording belongs to Threat 2.

**Threat 1.** Style fingerprints on machine-formatted handoffs (tool names, truncated state dumps, field ordering) are the hardest to fake by hand. The small n also invites the statistician to refuse to call it a pass. Per the judge's instruction, February's non-handoff result is not carried over. The risk is high.

**Threat 2.** Publication falls on the last day of the month, so in-month plaintiff uptake is limited. Staff asked for plain language and may catch the wording. The detector does run continuously, which partly defends the claim, but 88% recall on only 2 of 4 channels makes "continuously monitored" contestable. Moderate-low.

**Threat 3.** The statute sets the standard and the guidance comes later, so formal adoption of option (b) within March is unlikely. Signals that lean toward option (b) are plausible.

**Threat 4.** Several factors point to a slip or a request for more data: the agency carries a concurrent statutory deliverable, it is working to an indicative window, and the confidence bound sits near the threshold. Roughly a coin flip.

**Threat 5.** The release was previewed for spring and already missed February. The monthly hazard is meaningful but not dominant.
</analysis>

<action_odds>
Action 1 [Handoff pre-validation execution]: P(failure) 25%. Reason: Glasswing restrictions on sharing real partner handoffs with Apollo, redaction delays, and the monitoring backlog. The AUC outcome itself is modelled by Threat 1.
Action 2 [Main harness run]: P(failure) 60%. Reason: depends on Action 1 and Threat 1; the pre-registration timing conflicts; the non-handoff channels were at 0.58 against a 0.55 gate with no improvement step planned; Apollo's window closes on 31 March.
Action 3 [CAISI statutory briefing]: P(failure) 40%. Reason: getting the meeting is easy, but this is largely a replay of the February pitch that was not adopted, and the text is nearly final ahead of the 24 March deadline.
Action 4 [Site 3 acceleration to 8]: P(failure) 40%. Reason: a single biosafety officer, no-show rates, and base-rate slot losses of about 40% at comparable sites.
Action 5 [Blumenthal report finalisation]: P(failure) 20%. Reason: a pre-agreed template and engaged staff; the risks are counsel review timing and the harness and bio results still being in flux.
</action_odds>

<threat_odds>
Threat 1 [Handoff plants fail on authorship]: P(materialises) 60%. Adversary suggested 50%; I go higher because the December base rate was AUC 0.94, machine-formatted handoffs are the hardest channel to imitate by hand, and n=9 makes a defensible pass unlikely even on a borderline point estimate.
Threat 2 ["Monitored continuously" overstatement]: P(materialises) 20%. Adversary suggested 30%; I go lower because publication is on 31 March, leaving little room for in-month plaintiff uptake, staff may catch the wording, and continuous detector operation partly supports the claim.
Threat 3 [Option (b) becomes the floor]: P(materialises) 25%. Adversary suggested 35%; I go lower because the statute defers methods to later guidance, so a formal floor is unlikely in March, though leaning signals and board use of them are possible.
Threat 4 [CAISI bio decision slips or requests more data]: P(materialises) 50%. Adversary suggested 45%; I go slightly higher because of the concurrent statutory deliverable, a marginal upper confidence bound at n=37, and agencies' routine misses of indicative windows.
Threat 5 [OpenAI ships agentic GPT-7]: P(materialises) 35%. Adversary suggested 40%; I go slightly lower because it was previewed for spring and has already slipped once, so the monthly hazard is meaningful but OpenAI's review and security slowdown adds delay.
</threat_odds>
